Figure 3.

Cancer-specific survival. EST-3886, median follow-up 11.9 years; AST, androgen suppression therapy. (This figure should be published online only).

Kunath et al. BMC Cancer 2013 13:131   doi:10.1186/1471-2407-13-131
Download authors' original image